Tg Therapeutics (TGTX) Gains from Sales and Divestitures (2014 - 2026)

Tg Therapeutics' Gains from Sales and Divestitures history runs 13 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 14.28% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 14.28% YoY), while the FY2025 annual figure was $2.3 million, up 0.69% from the prior year.
• Gains from Sales and Divestitures was $1.6 million for Q1 2026 at Tg Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $6.3 million in Q4 2022 to a low of $1.2 million in Q1 2023.
• Historically, Gains from Sales and Divestitures has averaged $2.1 million across 5 years, with a median of $1.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures surged 382.98% in 2022, then plunged 60.26% in 2023.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $6.3 million in 2022, then slumped by 60.26% to $2.5 million in 2023, then declined by 9.91% to $2.3 million in 2024, then rose by 0.69% to $2.3 million in 2025, then fell by 27.86% to $1.6 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1.6 million (Q1 2026), $2.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.